Ipamorelin is one of the most-discussed growth-hormone-secretagogue peptides,
usually praised for its selectivity. This monograph covers what that selectivity
means and what the evidence base looks like.
Chemical identity & structure.
Ipamorelin is a synthetic pentapeptide (five amino acids). It belongs to the
class of growth hormone secretagogues that act as ghrelin mimetics — that is,
it activates the growth hormone secretagogue receptor (GHS-R), the same receptor
the natural hormone ghrelin acts on. It is a small, defined peptide, which makes
identity and purity verification straightforward.
Mechanism of action.
By agonizing the GHS-R, ipamorelin stimulates the pituitary to release growth
hormone in a pulse. Its notable feature, repeatedly reported in the literature,
is selectivity: compared with older secretagogues, ipamorelin stimulates GH
release with minimal effect on cortisol and prolactin. Because it acts upstream —
prompting the pituitary's own release rather than supplying GH directly — its
effect is constrained by the body's own regulatory feedback, unlike
administration of hGH itself.
Key research findings.
Ipamorelin was originally developed by a pharmaceutical company and entered
early clinical research before its development was discontinued for business
rather than safety reasons. The available literature — early clinical and
preclinical — documents reliable, relatively clean GH-release stimulation. There
is no large modern outcome trial program.
The research / citation base.
Ipamorelin is not an approved drug. Its evidence base is early clinical and
preclinical research from its original development era plus subsequent
preclinical work. It is well-characterized pharmacologically but not supported
by large efficacy trials for any specific outcome.
Human clinical trial data
In the phase 2 randomized, double-blind, placebo-controlled proof-of-concept trial by Beck and colleagues (2014) in 117 bowel-resection patients with postoperative ileus, the intervention was intravenous infusions of 0.03-mg/kg ipamorelin vs placebo twice daily, on postoperative day 1 to 7 or hospital discharge (PubMed); there were no significant differences between ipamorelin and placebo in the efficacy analyses.
Quality & sourcing notes.
As a small pentapeptide, ipamorelin should carry a batch-specific COA with mass-
spectrometry identity and HPLC purity (≥98% is a reasonable expectation). A
common market problem is mislabeling — verify that the vial contains ipamorelin
and not a cheaper substitute secretagogue.
*Research-use note: Educational summary of published research. Ipamorelin is not
an approved drug; this is research context only and not medical advice.*